Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.

Pharmacogenetics - 1 Apr 1998

Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to Cytochrome P-450 CYP2D6
Share to Debrisoquin
Share to DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Duplication

Share to Phenotype

Share to Sequence Deletion

Source

Identifiers

PMID: 10022755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.PMID 10022755Read ↗

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.Semantic proximity Read ↗

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Semantic proximity Read ↗

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.Semantic proximity Read ↗

New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.Semantic proximity Read ↗

Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification.Semantic proximity Read ↗

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.Semantic proximity Read ↗

Prediction of CYP2D6 phenotype from genotype across world populations.Semantic proximity Read ↗

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.Semantic proximity Read ↗

Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Substrate specificity of CYP2D6 genetic variants.Semantic proximity Read ↗

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.